Management recommendations for pancreatic manifestations of von Hippel–Lindau disease
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Von Hippel–Lindau disease (VHL) is a multineoplasm inherited disease manifesting with hemangioblastoma of the central nervous system and retina, adrenal pheochromocytoma, renal cell carcinoma, pancreatic neuroendocrine tumors and cysts, and neoplasms/cysts of the ear, broad ligament, and testicles. During 2018‐2020, the VHL Alliance gathered several committees of experts in the various clinical manifestations of VHL to review the literature, gather the available evidence on VHL, and develop recommendations for patient management. The current report details the results of the discussion of a group of experts in the pancreatic manifestations of VHL along with their proposed recommendations for the clinical surveillance and management of patients with VHL. The recommendations subcommittee performed a comprehensive systematic review of the literature and conducted panel discussions to reach the current recommendations. The level of evidence was defined according to the Shekelle variation of the Grading of Recommendations, Assessment, Development, and Evaluation grading system. The National Comprehensive Cancer Network Categories of Evidence and Consensus defined the committee members' interpretation of the evidence and degree of consensus. The recommendations encompass the main aspects of VHL‐related pancreatic manifestations and their clinical management. They are presented in a clinical orientation, including general planning of screening and surveillance for pancreatic neuroendocrine tumors, utility of biochemical biomarkers, the optimal choice for imaging modality, indirect risk stratification, indications for tissue sampling of VHL‐related pancreatic neuroendocrine tumors, and interventions. These recommendations are designed to serve as the reference for all aspects of the screening, surveillance, and management of VHL‐related pancreatic manifestations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers
O’Toole, D., Grossman, A., Gross, D., Delle Fave, G., Barkmanova, J., O’Connor, J., Pape, U.-F., & Plöckinger, U. (2009) · Neuroendocrinology · doi:10.1159/000225948 · Cited by 268
Xu, R., Wang, K., Rizzi, J. P., Huang, H., Grina, J. A., Schlachter, S. T., Wang, B., Wehn, P. M., Yang, H., Dixon, D. D., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00719 · Cited by 220
Imaging and localization of islet-cell tumours of the pancreas on CT and MRI.
Noone, T. C., Hosey, J., Firat, Z., & Semelka, R. C. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.11.013 · Cited by 217
Courtney, K. D., Ma, Y., Diaz de Leon, A., Christie, A., Xie, Z., Woolford, L., Singla, N., Joyce, A., Hill, H., Madhuranthakam, A. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1459 · Cited by 188
Research works printed but not linked: 79
- 10.1136/jmg.28.7.443 · DOI · Paper page
- 10.1016/0140-6736(91)91705-Y · DOI · Paper page
- 10.1126/science.8493574 · DOI · Paper page
- 10.1016/S0140-6736(03)13643-4 · DOI · Paper page
- 10.1677/ERC-10-0037 · DOI
- 10.1053/gast.2000.18143 · DOI · Paper page
- 10.1007/s00535-013-0794-1 · doi:10.1007/s00535-013-0794-1
- 10.1016/j.surg.2007.09.012 · doi:10.1016/j.surg.2007.09.012
- 10.1530/ERC-18-0100 · DOI
- 10.1159/000457956 · DOI · Paper page
- 10.1159/000443172 · DOI · Paper page
- 10.1001/jamaoncol.2017.3428 · DOI
- 10.1038/nrclinonc.2016.37 · DOI
- 10.1159/000443171 · DOI · Paper page
- 10.1097/MPA.0000000000001597 · DOI · Paper page
- 10.1136/bmj.318.7183.593 · DOI · Paper page
- NCCN Categories of Evidence and Consensus and NCCN Categories of Preference
- 10.1007/s10689-019-00131-x · DOI
- 10.1530/ERC-13-0308 · DOI
- 2021, Clinical care centers
- 10.1038/ejhg.2016.173 · DOI
- 10.1212/WNL.0000000000002064 · doi:10.1212/wnl.0000000000002064
- 10.1159/000472254 · DOI · Paper page
- 10.1016/j.jamcollsurg.2013.10.025 · DOI
- 10.1245/s10434-010-1006-3 · DOI · Paper page
- 10.1530/ERC-17-0269 · DOI · Paper page
- 10.1530/EJE-16-1079 · DOI
- 10.21037/jtd.2017.03.82 · DOI
- 10.1530/EC-20-0417 · DOI
- Al‐Toubah T, 2020, Sensitivity and specificity of the NETest: a validation study, Neuroendocrinology
- 10.1245/s10434-020-08464-z · doi:10.1245/s10434-020-08464-z
- 10.1159/000471879 · DOI · Paper page
- 10.1148/radiol.2253011297 · doi:10.1148/radiol.2253011297
- 10.1016/j.ejrad.2018.11.023 · doi:10.1016/j.ejrad.2018.11.023
- 10.1016/j.surg.2011.09.048 · DOI
- 10.1016/j.ejso.2007.07.209 · DOI
- 10.1530/EJE-15-1012 · doi:10.1530/eje-15-1012
- 10.3748/wjg.v18.i34.4659 · doi:10.3748/wjg.v18.i34.4659
- 10.1148/radiol.2018180687 · DOI
- 10.1016/j.jamcollsurg.2014.01.004 · DOI
- 10.1097/RLU.0000000000001315 · DOI
- 10.1097/RLU.0000000000001314 · DOI
- 10.1097/RLU.0000000000001393 · DOI
- 10.1097/RLU.0000000000001511 · DOI
- 10.1038/srep40822 · DOI
- 10.1007/s00259-016-3421-6 · DOI
- 10.1016/j.surg.2012.08.010 · doi:10.1016/j.surg.2012.08.010
- 10.12998/wjcc.v7.i23.4119 · doi:10.12998/wjcc.v7.i23.4119
- 10.1210/clinem/dgz314 · DOI
- 10.1097/SLA.0000000000000856 · DOI
- 10.1210/jc.2017-02434 · DOI
- 10.1186/s12893-020-01004-2 · DOI
- 10.1097/MPA.0000000000001454 · DOI · Paper page
- 10.1067/msy.2000.110239 · DOI
- 10.3748/wjg.v16.i36.4515 · doi:10.3748/wjg.v16.i36.4515
- 10.1097/MPA.0000000000000133 · DOI
- 10.4240/wjgs.v7.i4.52 · DOI · Paper page
- 10.1055/a-0824-7067 · DOI
- 10.1210/jc.2019-00282 · DOI
- 10.1016/j.ejso.2003.10.013 · doi:10.1016/j.ejso.2003.10.013
- 10.1159/000443167 · DOI · Paper page
- 10.1002/cncr.31930 · DOI
- 10.3389/fonc.2019.01122 · DOI
- 10.1056/NEJMoa1003825 · DOI · Paper page
- 10.1097/MCG.0000000000000160 · DOI
- 10.1080/15384047.2018.1470732 · DOI
- 10.1210/jc.2008-1972 · DOI
- 10.1097/MPA.0b013e31822a645e · DOI
- 10.1016/S1470-2045(18)30487-X · DOI · Paper page
- 10.18632/oncotarget.4564 · DOI
- 2021, FDA approves belzutifan for cancers associated with von Hippel–Lindau disease
- 10.1007/s11605-012-1847-0 · DOI
- 10.1001/archinte.1976.03630070017007 · doi:10.1001/archinte.1976.03630070017007
- 10.1097/MPA.0000000000000875 · DOI
- Medina D, 2014, Biliary and gastric drainage in advanced pancreatic serous cystadenoma and portal hypertension in von Hippel–Lindau syndrome, J Gastrointest Oncol, 5, E50
- 10.1007/s002689900234 · doi:10.1007/s002689900234
- Boujaoude J, 2007, A benign cause of obstructive jaundice with von Hippel–Lindau disease. A case report and review of the literature, JOP, 8, 790
- Deboever G, 1992, Common bile duct obstruction due to pancreatic involvement in the von Hippel–Lindau syndrome, Am J Gastroenterol, 87, 1866
- 10.1016/j.gcb.2008.01.041 · doi:10.1016/j.gcb.2008.01.041
Metadata
- Authors
- Laks, S., van Leeuwaarde, R., Patel, D., Keutgen, X. M., Hammel, P., Nilubol, N., Links, T. P., Halfdanarson, T. R., Daniels, A. B., Tirosh, A., & for the Pancreatic Manifestations Recommendations Development Subcommittee of the VHL Alliance
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2021-11-04
- Volume
- 128
- Issue
- 3
- Pages
- 435-446
- ISSN
- 0008-543X
- 1097-0142
- Cited by
- 51
- References
- 4
- Language
- en
- Funders
- National Eye Institute (5K08EY027464‐02)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.